Praxis der Hormontherapie in der Peri- und Postmenopause

@article{Wiegratz2007PraxisDH,
  title={Praxis der Hormontherapie in der Peri- und Postmenopause},
  author={Inka Wiegratz and Heike Ina Kuhl},
  journal={Gyn{\"a}kologische Endokrinologie},
  year={2007},
  volume={5},
  pages={141-149}
}
ZusammenfassungDie Hormontherapie in der Peri- und Postmenopause dient der Verbesserung der Lebensqualität und der Prävention von Erkrankungen, die durch einen längerfristigen Östrogenmangel verursacht oder verschlimmert werden. Als primäre Indikation gelten das klimakterische Syndrom und atrophische Veränderungen im Urogenitaltrakt. Die Behandlung sollte mit der niedrigsten effektiven Dosis begonnen und – wenn nötig – nach 4–6 Wochen angepasst werden. Eine Prävention sollte über mindestens 5… 
1 Citations

Hormontherapie mit Östrogenen und Gestagenen in der Peri- und Postmenopause

Hormone therapy with estrogens (combined with progestin for women who have not been hysterectomized) is the most efficacious treatment for climacteric symptoms.

References

SHOWING 1-10 OF 25 REFERENCES

Effects of low-dose hormone therapy on menopausal symptoms, bone mineral density, endometrium, and the cardiovascular system: a review of randomized clinical trials

Low-dose HT has been shown to improve menopausal and vulvovaginal atrophic symptoms, compared to placebo, and is less likely to give rise to unacceptable side-effects, including irregular bleeding and/or breast tenderness.

Hormone Therapy and Venous Thromboembolism Among Postmenopausal Women: Impact of the Route of Estrogen Administration and Progestogens: The ESTHER Study

Oral but not transdermal estrogen is associated with an increased VTE risk, and data suggest that norpregnane derivatives may be thrombogenic, whereas micronized progesterone and pregnane derivatives appear safe with respect toThrombotic risk.

Unopposed Estradiol Therapy in Postmenopausal Women: Results From Two Randomized Trials

Menopausal women choosing estradiol therapy, especially if obese, should anticipate uterine bleeding and the possibility of an endometrial biopsy, and short-term, unopposed est radiol therapy with gynecologic monitoring may be an option for the treatment of menopausal symptoms.

IMS Updated Recommendations on postmenopausal hormone therapy

  • Issued on behalf of the Board of the InternationalA. Pines N. Panay
  • Medicine
    Climacteric : the journal of the International Menopause Society
  • 2007
The International Menopause Society Board decided that it is time to update the 2004 Statement and to enlarge its scope to menopause management and adult women’s health in general.

Treatment of hot flashes with transdermal estradiol administration.

The data indicate that the transdermal delivery of E2 with these systems significantly reduced the occurrence of HFs and allowed definition of the therapeutic range of hormone replacement in terms of lost ovarian function, as reflected by circulating E2 levels.

Comparison of Continuation of Postmenopausal Hormone Replacement Therapy: Transdermal Versus Oral Estrogen

Among women starting HRT, those using a semiweekly transdermal estradiol regimen have a lower rate of continuation than do those using oral estrogen daily.

Prothrombotic Mutations, Hormone Therapy, and Venous Thromboembolism Among Postmenopausal Women: Impact of the Route of Estrogen Administration

In contrast to oral estrogen, transdermal estrogen does not confer additional risk on women who carry a prothrombotic mutation, and the safety of transDermal estrogen has to be confirmed in randomized trials.

The Effect of Low Dose Micronized 17β-Estradiol on Bone Turnover, Sex Hormone Levels, and Side Effects in Older Women: A Randomized, Double Blind, Placebo-Controlled Study1

The effects of three doses of micronized 17β-estradiol on bone turnover, sex hormone levels, and side effects compared with placebo in healthy older women in healthy, community-living women over 65 yr of age are examined.